Patents by Inventor Thomas Schmehl
Thomas Schmehl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230062605Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: October 17, 2022Publication date: March 2, 2023Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20220323459Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: May 16, 2022Publication date: October 13, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20220218720Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: March 29, 2022Publication date: July 14, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 11357782Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: September 27, 2021Date of Patent: June 14, 2022Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20220008436Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 10821116Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.Type: GrantFiled: September 29, 2016Date of Patent: November 3, 2020Assignee: VECTURA GMBHInventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Patent number: 10716793Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: January 31, 2020Date of Patent: July 21, 2020Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20200171044Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: January 31, 2020Publication date: June 4, 2020Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas Schmehl, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Publication number: 20190365778Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: August 9, 2019Publication date: December 5, 2019Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 10376525Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: February 1, 2016Date of Patent: August 13, 2019Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Patent number: 10258570Abstract: The invention relates to liposomes for pulmonary application, advantageously comprising at least one first and at least one second phospholipid, cholesterol, and at least one active substance and/or colorant, wherein the first phospholipid is a phosphatidylcholine, preferably DSPC, and the second phospholipid is a phosphatidylcholine or an ethanolamine, preferably selected from the group DMPC, DPPC, DPPE. It is thereby advantageous if the first and the second phospholipid are present at a molar ratio of 0.5:1 to 10:1, preferably at a ratio of 6:1 to 2:1, in particular preferably at a ratio of 3:1. It is further advantageous if the molar ratio between phospholipids and cholesterol is between 10:1 and 1:1, preferably between 6:1 and 3:1, in particular preferably 4:1. The second phospholipid is further preferably DMPC or DPPE, in particular preferably DPPE. The size of the liposomes is advantageously between 0.05 ?m and 5 ?m, preferably between 0.2 ?m and 2.Type: GrantFiled: June 29, 2010Date of Patent: April 16, 2019Assignee: Lung Biotechnology Inc.Inventors: Tobias Gessler, Thomas Schmehl, Monika Rieger
-
Publication number: 20170014424Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.Type: ApplicationFiled: September 29, 2016Publication date: January 19, 2017Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Patent number: 9486427Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.Type: GrantFiled: September 12, 2013Date of Patent: November 8, 2016Assignee: Vectura GMBHInventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Patent number: 9358240Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: November 12, 2009Date of Patent: June 7, 2016Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20160143868Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: ApplicationFiled: February 1, 2016Publication date: May 26, 2016Applicant: United Therapeutics CorporationInventors: Horst OLSCHEWSKI, Robert ROSCIGNO, Lewis J. RUBIN, Thomas SCHMEHL, Werner SEEGER, Carl STERRITT, Robert VOSWINCKEL
-
Patent number: 9339507Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.Type: GrantFiled: May 11, 2012Date of Patent: May 17, 2016Assignee: United Therapeutics CorporationInventors: Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel
-
Publication number: 20150290153Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. The administration is by inhalation over a short period of time, which is patient-friendly, effective, and well tolerated. Inhalation may, for example, be achieved using an efficient nebulizer based on the vibrating mesh technology.Type: ApplicationFiled: September 12, 2013Publication date: October 15, 2015Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Publication number: 20140155486Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.Type: ApplicationFiled: April 26, 2012Publication date: June 5, 2014Inventors: Tobias Gessler, Thomas Schmehl, Werner Seeger, Robert Voswinckel
-
Publication number: 20140127311Abstract: The present invention provides biocompatible nano-polymer particles which are composed of a biocompatible polymer, a stabilizer and an active agent for the treatment of pulmonary hypertension or erectile dysfunction and which can be used to produce a pharmaceutical preparation for the treatment of pulmonary hypertension or erectile dysfunction. Biocompatible nano-polymer particles of this invention have a diameter ranging from 10 nm to 10 ?m auf, a stabilizing layer thickness between 0 and 50 nm, contain between 0 and 50% of an active agent for the treatment of pulmonary hypertension or erectile dysfunction, are nebulizable and continuously release the active agent over a period of up to 48 hours. Biocompatible nano-polymer particles of this invention can be synthesized for example using the emulsion technique known to the expert with subsequent solvent evaporation or via spray drying.Type: ApplicationFiled: May 23, 2012Publication date: May 8, 2014Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Moritz Beck-Broichsitter, Thomas Schmehl, Tobias Gessler, Thomas Kissel
-
Publication number: 20140099379Abstract: The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. Biocompatible nano- and microparticles of this invention have a stabilizer layer thickness ranging from 1 to 200 nm and contain an active substance. Said biocompatible nano- and microparticles of this invention can be synthesized for example using the emulsion method known to the expert with subsequent coating by mixing of uncoated particles with the stabilizer, by chemical vapor deposition, by spraying or by covalent attachment.Type: ApplicationFiled: May 23, 2012Publication date: April 10, 2014Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Moritz Beck-Broichsitter, Tobias Gessler, Thomas Schmehl